Literature DB >> 25070421

Evaluation of class I HDAC isoform selectivity of largazole analogues.

Bumki Kim1, Heekwang Park1, Lilibeth A Salvador2, Patrick E Serrano1, Jason C Kwan3, Sabrina L Zeller1, Qi-Yin Chen4, Soyoung Ryu1, Yanxia Liu4, Seongrim Byeon1, Hendrik Luesch5, Jiyong Hong6.   

Abstract

Largazole is a potent class I selective histone deacetylase (HDAC) inhibitor. The majority of largazole analogues to date have modified the thiazole-thiazoline and the warhead moiety. In order to elucidate class I-specific structure-activity relationships, a series of analogues with modifications in the valine or the linker region were prepared and evaluated for their class I isoform selectivity. The inhibition profile showed that the C2 position of largazole has an optimal steric requirement for efficient HDAC inhibition and that substitution of the trans-alkene in the linker with an aromatic group results in complete loss of activity. This data will aid the design of class I isoform selective HDAC inhibitors.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Class I histone deacetylase; HDAC inhibitor; Isoform selectivity; Largazole; Structure–activity relationship

Mesh:

Substances:

Year:  2014        PMID: 25070421      PMCID: PMC4135083          DOI: 10.1016/j.bmcl.2014.07.006

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  27 in total

Review 1.  Deacetylase enzymes: biological functions and the use of small-molecule inhibitors.

Authors:  Christina M Grozinger; Stuart L Schreiber
Journal:  Chem Biol       Date:  2002-01

2.  Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents.

Authors:  Sajal K Ghosh; Susan P Perrine; Robert M Williams; Douglas V Faller
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

3.  Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: synthesis and biological evaluation.

Authors:  Pravin Bhansali; Christin L Hanigan; Robert A Casero; L M Viranga Tillekeratne
Journal:  J Med Chem       Date:  2011-10-10       Impact factor: 7.446

4.  Synthesis and biological activity of largazole and derivatives.

Authors:  Tobias Seiser; Faustin Kamena; Nicolai Cramer
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

5.  Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability.

Authors:  Hanae Benelkebir; Sabrina Marie; Annette L Hayden; Jason Lyle; Paul M Loadman; Simon J Crabb; Graham Packham; A Ganesan
Journal:  Bioorg Med Chem       Date:  2011-02-17       Impact factor: 3.641

6.  In Vitro and In Vivo Osteogenic Activity of Largazole.

Authors:  Su-Ui Lee; Han Bok Kwak; Sung-Hee Pi; Hyung-Keun You; Seong Rim Byeon; Yongcheng Ying; Hendrik Luesch; Jiyong Hong; Seong Hwan Kim
Journal:  ACS Med Chem Lett       Date:  2011-03-10       Impact factor: 4.345

7.  Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor.

Authors:  Yanxia Liu; Lilibeth A Salvador; Seongrim Byeon; Yongcheng Ying; Jason C Kwan; Brian K Law; Jiyong Hong; Hendrik Luesch
Journal:  J Pharmacol Exp Ther       Date:  2010-08-25       Impact factor: 4.030

8.  Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.

Authors:  José A Souto; Esther Vaz; Ilaria Lepore; Ann-Christin Pöppler; Gianluigi Franci; Rosana Alvarez; Lucia Altucci; Angel R de Lera
Journal:  J Med Chem       Date:  2010-06-24       Impact factor: 7.446

9.  Total synthesis and molecular target of largazole, a histone deacetylase inhibitor.

Authors:  Yongcheng Ying; Kanchan Taori; Hyoungsu Kim; Jiyong Hong; Hendrik Luesch
Journal:  J Am Chem Soc       Date:  2008-05-29       Impact factor: 15.419

10.  Synthesis and conformation-activity relationships of the peptide isosteres of FK228 and largazole.

Authors:  Albert A Bowers; Thomas J Greshock; Nathan West; Guillermina Estiu; Stuart L Schreiber; Olaf Wiest; Robert M Williams; James E Bradner
Journal:  J Am Chem Soc       Date:  2009-03-04       Impact factor: 15.419

View more
  11 in total

1.  Largazole is a Brain-Penetrant Class I HDAC Inhibitor with Extended Applicability to Glioblastoma and CNS Diseases.

Authors:  Fatma H Al-Awadhi; Lilibeth A Salvador-Reyes; Lobna A Elsadek; Ranjala Ratnayake; Qi-Yin Chen; Hendrik Luesch
Journal:  ACS Chem Neurosci       Date:  2020-06-19       Impact factor: 4.418

Review 2.  An overview of naturally occurring histone deacetylase inhibitors.

Authors:  Bumki Kim; Jiyong Hong
Journal:  Curr Top Med Chem       Date:  2015       Impact factor: 3.295

Review 3.  Biological targets and mechanisms of action of natural products from marine cyanobacteria.

Authors:  Lilibeth A Salvador-Reyes; Hendrik Luesch
Journal:  Nat Prod Rep       Date:  2015-03       Impact factor: 13.423

4.  Largazole Analogues Embodying Radical Changes in the Depsipeptide Ring: Development of a More Selective and Highly Potent Analogue.

Authors:  Jehad Almaliti; Ayad A Al-Hamashi; Ahmed T Negmeldin; Christin L Hanigan; Lalith Perera; Mary Kay H Pflum; Robert A Casero; L M Viranga Tillekeratne
Journal:  J Med Chem       Date:  2016-11-21       Impact factor: 7.446

5.  Synthesis and biological evaluation of largazole zinc-binding group analogs.

Authors:  Bumki Kim; Ranjala Ratnayake; Hyunji Lee; Guqin Shi; Sabrina L Zeller; Chenglong Li; Hendrik Luesch; Jiyong Hong
Journal:  Bioorg Med Chem       Date:  2017-04-04       Impact factor: 3.641

6.  Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site.

Authors:  Susan Matthew; Qi-Yin Chen; Ranjala Ratnayake; Charles S Fermaintt; Daniel Lucena-Agell; Francesca Bonato; Andrea E Prota; Seok Ting Lim; Xiaomeng Wang; J Fernando Díaz; April L Risinger; Valerie J Paul; Maria Ángela Oliva; Hendrik Luesch
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

7.  Unexpected Enhancement of HDACs Inhibition by MeS Substitution at C-2 Position of Fluoro Largazole.

Authors:  Bingbing Zhang; Zhu-Wei Ruan; Dongdong Luo; Yueyue Zhu; Tingbo Ding; Qiang Sui; Xinsheng Lei
Journal:  Mar Drugs       Date:  2020-06-30       Impact factor: 5.118

Review 8.  Recent Advances in Small Peptides of Marine Origin in Cancer Therapy.

Authors:  Qi-Ting Zhang; Ze-Dong Liu; Ze Wang; Tao Wang; Nan Wang; Ning Wang; Bin Zhang; Yu-Fen Zhao
Journal:  Mar Drugs       Date:  2021-02-19       Impact factor: 5.118

9.  Cells adapt to the epigenomic disruption caused by histone deacetylase inhibitors through a coordinated, chromatin-mediated transcriptional response.

Authors:  John A Halsall; Nil Turan; Maaike Wiersma; Bryan M Turner
Journal:  Epigenetics Chromatin       Date:  2015-09-16       Impact factor: 4.954

Review 10.  Cyanobacterial Metabolite Calothrixins: Recent Advances in Synthesis and Biological Evaluation.

Authors:  Su Xu; Bhavitavya Nijampatnam; Shilpa Dutta; Sadanandan E Velu
Journal:  Mar Drugs       Date:  2016-01-12       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.